semaglutide mastery course
Unit 6 of 7
type 2 diabetes and glycemic control
SUSTAIN and PIONEER programs, HbA1c trajectories, and treatment sequencing.
the original indication
This unit covers the SUSTAIN injectable trial program and PIONEER oral trial program that established semaglutide as a first-in-class GLP-1 RA for type 2 diabetes, HbA1c reduction benchmarks, head-to-head comparisons with other antidiabetic agents, and practical guidance on where semaglutide fits in modern treatment algorithms.
Interactive Simulator
Model HbA1c trajectories across different dosing regimens and patient profiles.
HbA1c trajectory simulator